Repression of IFN-γ expression by peroxisome proliferator-activated receptor γ

被引:70
|
作者
Cunard, R
Eto, Y
Muljadi, JT
Glass, CK
Kelly, CJ
Ricote, M
机构
[1] Vet Affairs San Diego Healthcare Syst, Res Serv, La Jolla, CA 92161 USA
[2] Vet Affairs San Diego Healthcare Syst, Div Nephrol Hypertens, La Jolla, CA 92161 USA
[3] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
来源
JOURNAL OF IMMUNOLOGY | 2004年 / 172卷 / 12期
关键词
D O I
10.4049/jimmunol.172.12.7530
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors expressed in a wide variety of cells. Our studies and others have demonstrated that both human and murine T cells express PPARgamma and that expression can be augmented over time in mitogen-activated splenocytes. PPARgamma ligands decrease proliferation and IL-2 production, and induce apoptosis in both B and T cells. PPARgamma ligands have also been shown to be anti-inflammatory in multiple models of inflammatory disease. In the following study, we demonstrate for the first time that PPARgamma is expressed in both murine CD4 and CD8 cells and that PPARgamma ligands directly decrease IFN-gamma expression by murine and transformed T cell lines. Unexpectedly, GW9662, a PPARgamma antagonist, increases lymphocyte IFN-gamma expression. Transient transfection studies reveal that PPARgamma ligands, in a PPARgamma-dependent manner, potently repress an IFN-gamma promoter construct. Repression localizes to the distal conserved sequence of the IFN-gamma promoter. Our studies also demonstrate that PPARgamma acts on the IFN-gamma promoter by interfering with c-Jun activation. These studies suggest that many of the observed anti-inflammatory effects of PPARgamma ligands may be related to direct inhibition of IFN-gamma by PPARgamma.
引用
收藏
页码:7530 / 7536
页数:7
相关论文
共 50 条
  • [31] Peroxisome proliferator-activated receptor γ and metabolic disease
    Willson, TM
    Lambert, MH
    Kliewer, SA
    ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 : 341 - 367
  • [32] The pleiotropic functions of peroxisome proliferator-activated receptor γ
    Debril, MB
    Renaud, JP
    Fajas, L
    Auwerx, J
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (01): : 30 - 47
  • [33] Peroxisome proliferator-activated receptor γ (PPARγ) and sepsis
    von Knethen, Andreas
    Soller, Mathias
    Bruene, Bernhard
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2007, 55 (01) : 19 - 25
  • [35] Peroxisome proliferator-activated receptor γ (PPARγ) and sepsis
    Andreas von Knethen
    Mathias Soller
    Bernhard Brüne
    Archivum Immunologiae et Therapiae Experimentalis, 2007, 55 : 19 - 25
  • [36] Evolution of peroxisome proliferator-activated receptor agonists
    Chang, Feng
    Jaber, Linda A.
    Berlie, Helen D.
    O'Connell, Mary Beth
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (06) : 973 - 983
  • [37] Peroxisome proliferator-activated receptor γ in diabetes and metabolism
    Rangwala, SM
    Lazar, MA
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (06) : 331 - 336
  • [38] PHYSIOLOGICAL FUNCTIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR β
    Neels, Jaap G.
    Grimaldi, Paul A.
    PHYSIOLOGICAL REVIEWS, 2014, 94 (03) : 795 - 858
  • [39] Peroxisome proliferator-activated receptor-γ and lipodystrophy
    Tantsma, Jouke T.
    Rabelink, Ton J.
    FUTURE LIPIDOLOGY, 2006, 1 (04): : 455 - 462
  • [40] ENANTIOSELECTIVE ACTIVATION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
    BOIE, Y
    ADAM, M
    RUSHMORE, TH
    KENNEDY, BP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (08) : 5530 - 5534